Aevi Genomic Medicine announces novel co-crystal version of AEVI-001
Aevi Genomic announce it received positive feedback from the FDA on an improved version of the Company's lead development molecule, AEVI-001, identified as AEVI-004. The FDA provisionally indicated that AEVI-004 is a co-crystal of AEVI-001 and a novel drug substance. July 19, 2018